Tesofensine (NS‑2330) is a novel oral serotonin–norepinephrine–dopamine reuptake inhibitor (TRI) originally explored for neurodegenerative diseases but repurposed for obesity after users experienced significant weight loss. In phase II trials, doses of 0.5 mg daily produced up to 10.6% body weight reduction over 24 weeks versus placebo.
Suppresses appetite by raising serotonin, norepinephrine, and dopamine activity
Modestly increases resting energy expenditure and fat oxidation
Achieved up to ~11.3 kg weight loss in six-month phase II trial (0.5 mg dose)
Well tolerated in trials; common side effects include dry mouth, nausea, insomnia, and mild cardiovascular changes
This website contains information about supplementary products. By entering, you confirm that you are of legal age (18 years or older) to access this information. If you are not of legal age, please leave this site immediately.
